{
    "version": "2.1.0",
    "lastUpdated": "2026-01-08",
    "evidenceSource": "CDC 2022, NCCN 2025, FDA Labels",
    "globalWarnings": [
        "MME calculations are for RISK STRATIFICATION and RESEARCH STANDARDIZATION only",
        "Do NOT use MME for direct clinical dose conversion",
        "When rotating opioids, reduce calculated dose by 25-50% for incomplete cross-tolerance",
        "Individual variability in genetics and pharmacokinetics cannot be accounted for",
        "Close monitoring and frequent dose titration required during opioid rotation",
        "WIDE VARIABILITY in conversion ratios exists (e.g. Tramadol 6.7±2.8, Hydromorphone 4.06±1.2). Verify MME consistency with YOUR INSTITUTION'S guidelines."
    ],
    "evidenceQualityDefinitions": {
        "high": "Multiple high-quality RCTs or systematic reviews with consistent results. Guideline consensus (CDC, NCCN). Direct clinical validation.",
        "moderate": "Single high-quality study, expert consensus, or pharmacokinetic modeling with clinical validation. Some variability in published ratios.",
        "low": "Pharmacokinetic extrapolation, theoretical derivation, or wide variability in published ratios. Limited clinical validation.",
        "insufficient": "No validated conversion factor available. Specialist consultation required."
    },
    "definitions": {
        "opioid_tolerant": "FDA Definition: Patients receiving, for ≥1 week, at least: 60 mg oral morphine/day, 25 mcg/hr transdermal fentanyl, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid.",
        "opioid_naive": "NCCN 2025: Patients not chronically receiving opioid analgesic on a daily basis and therefore have not developed significant tolerance.",
        "evidence_transparency": "NIH HEAL 2025 Analysis: Only 24 of 170,050 screened articles provided valid conversion evidence. Most studies have methodological flaws. ASCO 2023: Few studies compare potency across pain types (acute vs chronic, neuropathic vs nociceptive)."
    },
    "clinicalPharmacology": {
        "morphine_iv": {
            "familyId": "morphine_generic",
            "name": "Morphine",
            "subtitle": "Injectable (IV/SQ/IM)",
            "route": "IV",
            "mmeFactor": 3.0,
            "pkProfile": {
                "onset": "5-10 min",
                "peak": "20 min",
                "duration": "3-4 hrs",
                "bioavailability": null
            },
            "safetyProfile": {
                "renalNote": "Active Metabolites (M3G/M6G). Neurotoxic in failure.",
                "boxedWarning": "Respiratory Depression"
            },
            "citations": [
                "FDA Label 2024",
                "ASAM 2020"
            ]
        },
        "morphine_po_ir": {
            "familyId": "morphine_generic",
            "name": "Morphine",
            "subtitle": "Oral Tablet (IR)",
            "route": "PO",
            "mmeFactor": 1.0,
            "pkProfile": {
                "onset": "30-60 min",
                "peak": "60 min",
                "duration": "4 hrs",
                "bioavailability": "25-35%"
            },
            "safetyProfile": {
                "renalNote": "Active metabolites (M3G/M6G) accumulate in renal failure. M6G is potent/neurotoxic.",
                "boxedWarning": "Respiratory Depression"
            },
            "citations": [
                "FDA Label 2024",
                "CDC 2022",
                "Berger 2024"
            ]
        },
        "hydromorphone_iv": {
            "familyId": "hydromorphone_generic",
            "name": "Hydromorphone",
            "subtitle": "Injectable (IV/SQ/IM)",
            "route": "IV",
            "mmeFactor": 20.0,
            "pkProfile": {
                "onset": "5 min",
                "peak": "10-20 min",
                "duration": "2-4 hrs",
                "bioavailability": null
            },
            "safetyProfile": {
                "renalNote": "Safer than Morphine. Accumulation of H3G (Neuroexcitatory) in failure.",
                "boxedWarning": "Respiratory Depression"
            },
            "citations": [
                "FDA Label 2024",
                "NCCN 2025"
            ]
        },
        "hydromorphone_po_ir": {
            "familyId": "hydromorphone_generic",
            "name": "Hydromorphone",
            "subtitle": "Oral Tablet (IR)",
            "route": "PO",
            "mmeFactor": 4.0,
            "pkProfile": {
                "onset": "15-30 min",
                "peak": "30-60 min",
                "duration": "3-4 hrs",
                "bioavailability": "62%"
            },
            "safetyProfile": {
                "renalNote": "H3G Accumulation Risk (Neuroexcitatory/Seizures).",
                "boxedWarning": "High Potency - Check Dose"
            },
            "citations": [
                "FDA Label 2024"
            ]
        },
        "oxycodone_po_ir": {
            "familyId": "oxycodone_generic",
            "name": "Oxycodone",
            "subtitle": "Oral Tablet (IR)",
            "route": "PO",
            "mmeFactor": 1.5,
            "pkProfile": {
                "onset": "10-15 min",
                "peak": "30-60 min",
                "duration": "3-6 hrs",
                "bioavailability": "60-87%"
            },
            "safetyProfile": {
                "renalNote": "Active metabolites (Noroxycodone). Use caution in impairment.",
                "boxedWarning": "Addiction, Abuse, and Misuse"
            },
            "citations": [
                "FDA Label 2024",
                "CDC 2022"
            ]
        },
        "fentanyl_iv": {
            "familyId": "fentanyl_generic",
            "name": "Fentanyl",
            "subtitle": "Injectable (IV)",
            "route": "IV",
            "mmeFactor": 0.13,
            "pkProfile": {
                "onset": "Immediate",
                "peak": "3-5 min",
                "duration": "0.5-1 hr",
                "bioavailability": null
            },
            "safetyProfile": {
                "renalNote": "Appears safe. Inactive metabolites.",
                "boxedWarning": "Life-Threatening Respiratory Depression"
            },
            "citations": [
                "FDA Label 2024",
                "NCCN 2025"
            ]
        },
        "fentanyl_patch": {
            "familyId": "fentanyl_generic",
            "name": "Fentanyl",
            "subtitle": "Transdermal Patch",
            "route": "PATCH",
            "mmeFactor": 2.4,
            "pkProfile": {
                "onset": "12-24 hrs (Delayed)",
                "peak": "20-72 hrs",
                "duration": "72 hrs",
                "bioavailability": "92%"
            },
            "safetyProfile": {
                "renalNote": "Safe, but difficult to titrate in unstable patients.",
                "boxedWarning": "FATAL in Opioid Naive. Heat increases absorption."
            },
            "citations": [
                "FDA Label 2024",
                "CDC 2022"
            ]
        },
        "methadone_iv": {
            "familyId": "methadone_generic",
            "name": "Methadone",
            "subtitle": "Injectable (IV)",
            "route": "IV",
            "mmeFactor": 4.7,
            "pkProfile": {
                "onset": "10-20 min",
                "peak": "30-60 min",
                "duration": "Variable (4-8 hrs Analgesia)",
                "bioavailability": null
            },
            "safetyProfile": {
                "renalNote": "Safe (Fecal excretion). Watch for QT Prolongation.",
                "boxedWarning": "QT Prolongation & Torsades de Pointes"
            },
            "citations": [
                "FDA Label 2024",
                "ASAM 2020"
            ]
        },
        "methadone_po": {
            "familyId": "methadone_generic",
            "name": "Methadone",
            "subtitle": "Oral Tablet",
            "route": "PO",
            "mmeFactor": 4.7,
            "pkProfile": {
                "onset": "30-60 min",
                "peak": "1-3 hrs",
                "duration": "Variable (4-8 hrs Analgesia)",
                "bioavailability": "80-100%"
            },
            "safetyProfile": {
                "renalNote": "Safe (Fecal excretion). Watch for QT Prolongation.",
                "boxedWarning": "QT Prolongation & Respiratory Depression (Late Onset)"
            },
            "citations": [
                "FDA Label 2024",
                "ASAM 2020"
            ]
        }
    },
    "conversionFactors": {
        "fentanyl": {
            "routes": [
                {
                    "route": "iv_acute",
                    "factor": 0.3,
                    "unit": "mcg/day",
                    "evidenceQuality": "high",
                    "source": "FDA Label + NCCN 2025",
                    "citation": "100 mcg IV fentanyl = 10 mg IV morphine (single-dose)",
                    "clinicalContext": "For bolus dosing, PRN administration, or short-duration infusions."
                },
                {
                    "route": "iv_continuous",
                    "factor": 0.12,
                    "unit": "mcg/day",
                    "evidenceQuality": "moderate",
                    "source": "NCCN 2025",
                    "citation": "Steady-state ratio 250 mcg IV fentanyl = 10 mg IV morphine",
                    "clinicalContext": "For continuous infusions >24 hours. Accounts for accumulation and context-sensitive half-life.",
                    "temporalThreshold": "24 hours",
                    "pharmacokineticRationale": "Fentanyl accumulates in skeletal muscle and fat (Vd 6 L/kg). Terminal t½ 219 minutes. Steady-state reached after ~5 half-lives (18 hours)."
                },
                {
                    "route": "transdermal",
                    "factor": 2.4,
                    "unit": "mcg/hr",
                    "evidenceQuality": "high",
                    "source": "CDC 2022",
                    "citation": "25mcg/hr Fentanyl ≈ 60 MME",
                    "warnings": [
                        "DANGER: Do not use in Opioid Naive patients",
                        "Patches have delayed onset (12-24h) and offset",
                        "Absorption increased by heat (fever, heating pads) - RISK OF OVERDOSE (CDC 2022)",
                        "Cachexia: Poor absorption in patients with little subcutaneous fat"
                    ],
                    "clinicalContext": "EAPC recommends 100:1 ratio (Oral Morphine:Transdermal Fentanyl). ONLY for Opioid Tolerant patients (FDA: 60mg MS, 30mg Oxy, 8mg Hydro, 25mcg Fent for ≥1 week)."
                }
            ]
        },
        "hydromorphone": {
            "routes": [
                {
                    "route": "iv",
                    "factor": 20.0,
                    "unit": "mg/day",
                    "evidenceQuality": "moderate",
                    "source": "NCCN 2025 / Clinical Standard",
                    "citation": "1.5mg IV HM = 10mg IV MS = 30mg PO MS (Ratio 20:1)",
                    "clinicalContext": "Factor 20.0 aligns with standard equianalgesic table. 1.5mg IV Dilaudid is approx 30 MME. Previous factor (6.7) was too conservative."
                },
                {
                    "route": "po",
                    "factor": 4.0,
                    "unit": "mg/day",
                    "evidenceQuality": "high",
                    "source": "CDC 2022",
                    "citation": "Standard 1:4 ratio (7.5mg HM = 30 MME)",
                    "clinicalContext": "Standard oral conversion."
                },
                {
                    "route": "iv_continuous",
                    "factor": 20.0,
                    "unit": "mg/day",
                    "evidenceQuality": "moderate",
                    "source": "Clinical Estimate",
                    "citation": "Same as IV Push.",
                    "clinicalContext": "Continuous infusion."
                }
            ]
        },
        "morphine_iv": {
            "routes": [
                {
                    "route": "iv",
                    "factor": 3.0,
                    "unit": "mg/day",
                    "evidenceQuality": "high",
                    "source": "CDC 2022 / Mercadante 2010",
                    "citation": "Chronic dosing ratio 1:3 (IV:PO)",
                    "clinicalContext": "Standard chronic ratio (1:3). Acute rotation often uses 1:6 ratio due to incomplete cross-tolerance. Mercadante 2010 supports 1:2.5-1:3 for chronic."
                },
                {
                    "route": "iv_continuous",
                    "factor": 3.0,
                    "unit": "mg/day",
                    "evidenceQuality": "high",
                    "source": "CDC 2022",
                    "citation": "Reference Standard (1 mg = 1 MME)",
                    "clinicalContext": "Continuous infusion."
                }
            ]
        },
        "morphine_po_ir": {
            "routes": [
                {
                    "route": "po",
                    "factor": 1.0,
                    "unit": "mg/day",
                    "evidenceQuality": "high",
                    "source": "CDC 2022",
                    "citation": "Reference Standard (1 mg = 1 MME)",
                    "clinicalContext": "Reference Standard."
                }
            ]
        },
        "methadone": {
            "routes": [
                {
                    "route": "po",
                    "factor": 4.7,
                    "unit": "mg/day",
                    "evidenceQuality": "low",
                    "source": "CDC 2022",
                    "citation": "CDC conversion factor for MME calculation only. NOT for dose conversion.",
                    "clinicalContext": "FOR RISK STRATIFICATION ONLY. Methadone conversion is non-linear and dose-dependent (ratios 2:1 to 20:1). When converting TO methadone, use tiered ratios.",
                    "warnings": [
                        "NON-LINEAR: Conversion ratio changes with dose",
                        "DO NOT use this factor to convert FROM methadone to other opioids",
                        "Risk Stratification ONLY"
                    ]
                },
                {
                    "route": "iv",
                    "factor": 4.7,
                    "unit": "mg/day",
                    "evidenceQuality": "low",
                    "source": "Clinical Estimate",
                    "citation": "Using conservative PO factor (bioavailability ~80%).",
                    "clinicalContext": "IV Methadone is roughly equipotent to PO. Used conservative estimate.",
                    "warnings": [
                        "HIGH VARIABILITY",
                        "Risk Stratification ONLY"
                    ]
                }
            ]
        },
        "oxycodone": {
            "routes": [
                {
                    "route": "po",
                    "factor": 1.5,
                    "unit": "mg/day",
                    "evidenceQuality": "high",
                    "source": "CDC 2022",
                    "citation": "Standard 1.5:1 ratio",
                    "clinicalContext": "Consistent across guidelines."
                }
            ]
        },
        "oxymorphone": {
            "routes": [
                {
                    "route": "po",
                    "factor": 3.0,
                    "unit": "mg/day",
                    "evidenceQuality": "moderate",
                    "source": "FDA Label",
                    "citation": "Approximately 3x potency of oral morphine",
                    "clinicalContext": "Potent mu-agonist. 10mg Oral Oxymorphone ≈ 30mg Oral Morphine."
                },
                {
                    "route": "iv",
                    "factor": 30.0,
                    "unit": "mg/day",
                    "evidenceQuality": "low",
                    "source": "Clinical Estimate",
                    "citation": "Estimated 10:1 IV:PO ratio (1mg IV ≈ 10mg PO ≈ 30mg Morphine)",
                    "clinicalContext": "Use extreme caution. IV formulation rarely used."
                }
            ]
        },
        "tramadol": {
            "routes": [
                {
                    "route": "po",
                    "factor": 0.0,
                    "unit": "mg/day",
                    "evidenceQuality": "high",
                    "source": "Clinical Consensus",
                    "citation": "Excluded from MME due to dual mechanism & metabolic variability.",
                    "warnings": [
                        "Dual Mechanism: Mu-opioid + SNRI activity makes MME unreliable",
                        "Metabolic Variability: CYP2D6 dependence causes variable potency",
                        "Seizure risk >400mg/day",
                        "Serotonin Syndrome risk"
                    ],
                    "clinicalContext": "Excluded from MME. Traditionally 0.1-0.2, but nonlinear."
                }
            ]
        },
        "codeine": {
            "routes": [
                {
                    "route": "po",
                    "factor": 0.15,
                    "unit": "mg/day",
                    "evidenceQuality": "moderate",
                    "source": "CDC 2022",
                    "citation": "200mg Codeine ≈ 30 MME",
                    "clinicalContext": "Prodrug requiring CYP2D6 metabolism. Genetic variability affects efficacy."
                }
            ]
        },
        "tapentadol": {
            "routes": [
                {
                    "route": "po",
                    "factor": 0.0,
                    "unit": "mg/day",
                    "evidenceQuality": "high",
                    "source": "Clinical Consensus",
                    "citation": "Excluded from MME due to dual mechanism (MOR-NRI).",
                    "warnings": [
                        "Dual Mechanism: Mu-opioid + NRI activity makes MME unreliable",
                        "Lower GI side effect profile vs pure agonists"
                    ],
                    "clinicalContext": "Excluded from MME. Traditionally ~0.4, but nonlinear."
                }
            ]
        },
        "hydrocodone": {
            "routes": [
                {
                    "route": "po",
                    "factor": 1.0,
                    "unit": "mg/day",
                    "evidenceQuality": "high",
                    "source": "CDC 2022",
                    "citation": "1:1 conversion with Morphine",
                    "clinicalContext": "Standard 1:1 ratio. WARNING: Available only in combination with Acetaminophen (APAP) or Ibuprofen. Limit APAP < 4000mg/day (FDA limited tablets to 325mg APAP)."
                }
            ]
        },
        "suzetrigine": {
            "routes": [
                {
                    "route": "po",
                    "factor": 0.0,
                    "unit": "mg/day",
                    "evidenceQuality": "high",
                    "source": "FDA Label (VX-548)",
                    "citation": "Non-Opioid NaV1.8 Inhibitor. Zero MME.",
                    "warnings": [
                        "Non-Opioid: Do not use for withdrawal management",
                        "Renal: Avoid in eGFR < 15 or Dialysis"
                    ],
                    "clinicalContext": "First-in-class NaV1.8 Inhibitor. Indicated for moderate-to-severe acute pain. No physical dependence risk."
                }
            ]
        },
        "levorphanol": {
            "routes": [
                {
                    "route": "po",
                    "factor": 8.0,
                    "unit": "mg/day",
                    "evidenceQuality": "moderate",
                    "source": "FDA Label 2026",
                    "citation": "4-8x potency of morphine (Used upper limit 8x).",
                    "warnings": [
                        "Long half-life (11-16h)",
                        "Accumulation risk similar to methadone"
                    ],
                    "clinicalContext": "Potent NMDA antagonist properties. Used for refractory pain."
                }
            ]
        },
        "meperidine": {
            "routes": [
                {
                    "route": "po",
                    "factor": 0.1,
                    "unit": "mg/day",
                    "evidenceQuality": "low",
                    "source": "Legacy / Equianalgesic Tables",
                    "citation": "300mg Meperidine ≈ 30mg Morphine",
                    "warnings": [
                        "NOT RECOMMENDED for chronic pain",
                        "Neurotoxic metabolite (Normeperidine)",
                        "Seizure risk",
                        "Serotonin Syndrome",
                        "Avoid in elderly/renal failure",
                        "Oral efficacy significantly less than parenteral (Variable)"
                    ],
                    "clinicalContext": "NOT RECOMMENDED. Poor oral bioavailability (<50%). MME factor (0.1) likely OVERESTIMATES potency; use caution when rotating FROM Meperidine (risk of overdosing new drug)."
                },
                {
                    "route": "iv",
                    "factor": 0.4,
                    "unit": "mg/day",
                    "evidenceQuality": "low",
                    "source": "Legacy",
                    "citation": "75mg IV Meperidine ≈ 30mg Morphine",
                    "clinicalContext": "Short duration. Neurotoxic risk remains."
                }
            ]
        },
        "buprenorphine": {
            "routes": [
                {
                    "route": "transdermal",
                    "factor": 0.0,
                    "unit": "mcg/hr",
                    "evidenceQuality": "high",
                    "source": "CDC 2022",
                    "citation": "Excluded from MME calculation due to partial agonism and ceiling effect (CDC 2022).",
                    "warnings": [
                        "Partial Agonist: Ceiling effect on respiratory depression & analgesia",
                        "Precipitated Withdrawal risk if full agonist on board",
                        "QT Prolongation risk >20mcg/hr (FDA warning context: risk mainly at supratherapeutic >40mcg)",
                        "NIH HEAL 2025: Calculator excludes by default but acknowledges emerging role in pain analysis"
                    ],
                    "clinicalContext": "Use cautiously. Not suitable for acute pain MME conversion. NIH HEAL 2025 calculator allows optional analysis."
                },
                {
                    "route": "sl",
                    "factor": 0.0,
                    "unit": "mg",
                    "evidenceQuality": "high",
                    "source": "CDC 2022",
                    "citation": "Excluded from MME calculations",
                    "warnings": [
                        "Partial Agonist - MME not applicable"
                    ],
                    "clinicalContext": "Sublingual bioavailability widely variable."
                }
            ]
        },
        "sufentanil": {
            "routes": [
                {
                    "route": "iv",
                    "factor": 0.0,
                    "unit": "mcg",
                    "evidenceQuality": "low",
                    "source": "Anesthesia Textbooks",
                    "citation": "Excluded from MME. Anesthesia/ICU use only.",
                    "warnings": [
                        "Standard conversion not applicable to outpatient settings",
                        "Potent Anesthetic (500-1000x Morphine)",
                        "ICU/OR Setting Only"
                    ],
                    "clinicalContext": "Extreme potency. Not for general ward use."
                }
            ]
        },
        "alfentanil": {
            "routes": [
                {
                    "route": "iv",
                    "factor": 0.0,
                    "unit": "mcg",
                    "evidenceQuality": "low",
                    "source": "Anesthesia Textbooks",
                    "citation": "Excluded from MME. Anesthesia/ICU use only.",
                    "warnings": [
                        "Standard conversion not applicable to outpatient settings",
                        "Short duration",
                        "ICU/OR Setting Only"
                    ],
                    "clinicalContext": "Rapid onset/offset. Factor derived from 15x Morphine potency."
                }
            ]
        },
        "butorphanol": {
            "routes": [
                {
                    "route": "iv",
                    "factor": 0.0,
                    "unit": "mg",
                    "evidenceQuality": "high",
                    "source": "Clinical Consensus",
                    "citation": "Excluded from MME due to mixed agonist/antagonist activity.",
                    "warnings": [
                        "Mixed Agonist/Antagonist: Nonlinear equivalency",
                        "May precipitate withdrawal in patients on full agonists",
                        "Psychotomimetic effects (Kappa agonism)"
                    ],
                    "clinicalContext": "Used in labor/migraine. Not interchangeable with pure agonists."
                }
            ]
        },
        "nalbuphine": {
            "routes": [
                {
                    "route": "iv",
                    "factor": 0.0,
                    "unit": "mg",
                    "evidenceQuality": "high",
                    "source": "Clinical Consensus",
                    "citation": "Excluded from MME due to mixed agonist/antagonist activity.",
                    "warnings": [
                        "Mixed Agonist/Antagonist: Nonlinear equivalency",
                        "Ceiling effect on respiratory depression",
                        "May precipitate withdrawal in patients on full agonists"
                    ],
                    "clinicalContext": "Used in procedural sedation/labor."
                }
            ]
        },
        "pentazocine": {
            "routes": [
                {
                    "route": "po",
                    "factor": 0.0,
                    "unit": "mg",
                    "evidenceQuality": "high",
                    "source": "Clinical Consensus",
                    "citation": "Excluded from MME due to mixed agonist/antagonist activity.",
                    "warnings": [
                        "Mixed Agonist/Antagonist: Nonlinear equivalency",
                        "May precipitate withdrawal in patients on full agonists",
                        "High risk of psychotomimetic effects (hallucinations/dysphoria)"
                    ],
                    "clinicalContext": "Historic use. Generally avoided."
                }
            ]
        },
        "loperamide": {
            "routes": [
                {
                    "route": "po",
                    "factor": 0.0,
                    "unit": "mg",
                    "evidenceQuality": "high",
                    "source": "Clinical Consensus",
                    "citation": "Excluded from MME. Peripheral action only.",
                    "warnings": [
                        "Peripheral Only: No central analgesia at therapeutic doses",
                        "High doses required for CNS effect cause cardiotoxicity (QRS widening)"
                    ],
                    "clinicalContext": "Antidiarrheal."
                }
            ]
        },
        "diphenoxylate": {
            "routes": [
                {
                    "route": "po",
                    "factor": 0.0,
                    "unit": "mg",
                    "evidenceQuality": "high",
                    "source": "Clinical Consensus",
                    "citation": "Excluded from MME. Peripheral action only.",
                    "warnings": [
                        "Peripheral Only: No central analgesia",
                        "Contains Atropine to discourage abuse"
                    ],
                    "clinicalContext": "Antidiarrheal."
                }
            ]
        }
    }
}